North America Is Dominating Wearable Injectors Industry

The global wearable injectors market is projected to be worth USD 20.21 billion by 2030, growing at a CAGR of 12.6%. This growth can be credited to the rising concerns over health risks because of the conventional injectors, along with the surging demand for new and conventional medication molecules. 

Furthermore, the growing count of cases of chronic illnesses, like cardiovascular illnesses, diabetes, and cancer, and supportive reimbursement strategies are projected to fortify the domain in the coming few years.

In recent years, the on-body wearable injector category had the largest wearable injectors revenue share of above 50%, because of the user suitability and water resistance of these patches.

The body-worn patch injector is attached to the body via a glue patch, typically on the abdomen, for controlled input of medications subcutaneously. It is either loaded or preloaded with the medication at the time of application. Furthermore, it is a one-time-use device that can be dumped once the medicine delivery is done.

In recent years, North America dominated the wearable injectors market, with over 30% revenue share. The wide biologics pipeline and the growing load of chronic illnesses are boosting the development of the domain in the continent. Furthermore, the high performance and convenience of using wearable injectors in the case of certain illnesses, like autoimmune disorders, cancer, and hematologic syndromes, are projected to surge their utilization in the continent.

Hence, the rising concerns over health risks because of the conventional injectors, along with the surging demand for new and conventional medication molecules, are the major factors contributing to the growth of the market.

Report this Page